Management of febrile neutropenia: ESMO Clinical Practice Guidelines. - Wikidata - awgldk - TriplyDB

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

http://www.wikidata.org/entity/Q34620670

about

Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution Colony-stimulating factors for chemotherapy-induced febrile neutropenia Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients Oncological emergencies associated with gastrointestinal tumors Factors associated with hospital length of stay among cancer patients with febrile neutropenia Bacterial Landscape of Bloodstream Infections in Neutropenic Patients via High Throughput Sequencing The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review Infections in Cancer Patients with Solid Tumors: A Review.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage.Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms.A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia Pharmacotherapy of fever control among hospitalized adult patients.Febrile neutropenia in hematologic malignancies.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Which Multidrug-Resitant Bacteria are Emerging in Patients with Hematological Malignancies?: One-Year Report.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Response of first-line antibiotic therapy in patients with febrile neutropenia during treatment of hematological disorders.Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?Febrile neutropenia in chemotherapy treated small-cell lung cancer patients Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.Predictive performance of Vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation.Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience.Metagenomic analysis of bloodstream infections in patients with acute leukemia and therapy-induced neutropenia.Communicating safe outpatient management of fever and neutropenia.Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline.The outcome of non-carbapenem-based empirical antibacterial therapy and VRE colonisation in patients with hematological malignancies Outcome of severe infections in afebrile neutropenic cancer patients.Vancomycin Pharmacokinetic Parameters in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT).Socio-demographic Characteristics of Patients with Diagnosis of Leukemia in Bosnia and Herzegovina During Six-year Period.Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit.The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

P2860

Q24185821-4E392BED-C155-4AF2-A482-33C98DB3D3E1 Q24193040-D83D1482-5289-467A-82D0-343AB0FCECD1 Q26768126-44929D13-9940-4A13-A777-4DFDF5D24B94 Q26783725-55BD1CC9-E580-4B0A-B2A7-70F369F26F53 Q28543554-EC3664DB-0875-4B59-A0AE-6CC93FB27DB4 Q28547252-4F8E9998-F9A6-4C36-8181-91B840F790DE Q29994513-F0AB57A3-CAFD-4310-AB81-A7CC9FC268F0 Q30238576-6392C63A-2CF1-4E5C-ADAF-92DDD84513E3 Q33413142-8A22C766-E822-4FA3-99F7-0918BF57C37A Q33573641-5A17836F-59B5-434F-AD1B-BC9CC34AB000 Q33690666-F17A9A6A-4946-4FF3-96A7-F1BC43F6661D Q34174170-291BB7AA-0CC3-4F13-9461-BB0FCEF3997B Q34333814-B037AD39-688C-4981-A181-013F014C5278 Q34403621-4DA7E0EA-320B-4872-9D18-1AC84B52C9BB Q34621396-5ECE836A-DDC5-449B-9D54-3E3D9467BD74 Q34655730-84DE01ED-28EB-401E-B10D-5522A1CF42E0 Q34667166-51BB7360-4C5B-4A7E-876F-494BFE244CD1 Q34670717-0C1DEE88-F900-441F-8CE0-C3E2644ECEB0 Q34766770-43B5A43A-F6A5-471A-899C-DE6868C4617F Q35044368-32C22E3B-F540-4B58-93FA-6A78F34B70D8 Q35220785-D4339471-7099-4107-ADFD-40FABBB4E83A Q35220799-126D0493-CB38-490E-8240-244B27A0776F Q35297079-60590D37-2FE9-411D-86CB-B00F80977E92 Q35753638-BFA96838-AF7B-4704-942D-92968109EA83 Q35993369-E99A933D-4469-4F5D-9941-B1902920A1C1 Q36007020-9A374402-671E-47F2-8A56-73F614E6B168 Q36059234-3ADFF9C5-E2DE-4ACC-8B8E-C6E6160A8C5F Q36289980-F3EEBBB2-4BD6-42A8-A2D3-18DBD95538C2 Q36452230-347E5765-7F5B-4133-99E3-9C54583EB650 Q36569874-473F860E-8E2F-4CDD-97B8-FF929DCB5A94 Q36709092-560EE8E4-77DB-4F07-9B47-7AB996F97128 Q37008525-913EA6AF-85EA-4DF6-BD86-DFCACEAC0DDE Q37152897-05D35E08-3303-4BA9-9260-658FF532C9D6 Q37299105-4FB3FE3D-2113-4CC3-A6AA-281316A3CB5E Q37432031-35469F48-649E-4648-B84F-7C76AB5468E8 Q37560043-09931803-75CA-4962-B6FE-F9D67489D71D Q37588507-99B35639-B0FC-45FA-8075-DF44F971A611 Q37737572-1E2F28F6-C950-4E0D-8188-D7A81943CBF6 Q37868641-6EC3B263-685F-48BB-9253-39D45DA781BC Q38084890-5712FA45-F878-48D3-BDA7-1C1505BB5E17

P2860

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

http://www.wikidata.org/entity/Q34620670

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@ast

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@en

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@nl

type

label

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@ast

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@en

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@nl

prefLabel

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@ast

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@en

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@nl

P1433

Q34620670-03685E46-671A-4310-836B-A12D47633F5C

P1476

Q34620670-67292F05-0C40-48AE-8A5B-1537B6F4AD54

P2093

Q34620670-0D5A20F1-DE59-4E98-B31B-78D50FE15C7B

Q34620670-289546CF-A0D5-4E9A-BB81-D1C510554D62

Q34620670-3CFFEF97-6A37-4DA2-A64E-827C0DF2306E

Q34620670-5A6F8B18-F73A-4117-9B88-6EE218BDFD3F

Q34620670-8C49D3CD-F559-48A0-9642-77A3BCB8736B

Q34620670-D3835C50-29C9-4475-8AE5-D6F1BE4D0B2C

Q34620670-FF18F25F-BE6C-48CD-A107-24FBB4DD7C46

P2860

Q34620670-069F939F-7223-4991-A2C3-D6C2B55C23C0

Q34620670-18F0DC75-A6B1-4EA5-A8A3-0C539C5638BA

Q34620670-1CB2B2A9-0F6C-46CB-B0D8-D788AE3AA494

Q34620670-3524327D-5BA8-4B01-9FD2-63D410BE08E0

Q34620670-5DFDB42F-5ABC-4064-A861-A7BC33EAA7DE

Q34620670-750BA53D-F74B-4250-8A13-276DBD3534B8

Q34620670-7BE8CE54-3819-4AE7-BC82-D91C57A43036

Q34620670-7EBAC26B-1EC4-45B3-9611-AB1FE1D27DD8

Q34620670-7EEA5829-C55F-4B06-B2B5-4E33E2142F6C

Q34620670-9439242F-BFB4-4BE2-B8BF-6933036F457F

P304

Q34620670-2C716751-B627-4E2E-BCFE-19A567F8F68B

P31

Q34620670-29770B29-38FF-4575-9A6B-3DF63E13B28C

P356

Q34620670-A0C41C4E-FBA2-42C4-AA4B-ED6F51332EF3

P478

Q34620670-E48CEE45-DDA9-4676-8165-98A66A41BDE6

P577

Q34620670-C0FA1529-3724-41E6-8DCE-94B89D895FB9

P5875

Q34620670-C400E345-5BD8-4066-B911-70C3E1FC36CD

P698

Q34620670-8072DC11-A406-4F6A-AA65-6D3EE157865B

P356

P1433

Annals of Oncology

P1476

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

@en

P2093

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

F Marti Marti

http://www.w3.org/2001/XMLSchema#string

F Roila

http://www.w3.org/2001/XMLSchema#string

I Novitzky-Basso

http://www.w3.org/2001/XMLSchema#string

J de Naurois

http://www.w3.org/2001/XMLSchema#string

M H Cullen

http://www.w3.org/2001/XMLSchema#string

M J Gill

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.

Central venous catheter-related infections in hematology and oncology : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.

Patients at high risk of invasive fungal infections: when and how to treat.

Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis.

P304

v252-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ196

http://www.w3.org/2001/XMLSchema#string

P478

21 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51443576

http://www.w3.org/2001/XMLSchema#string

P698

20555092

http://www.w3.org/2001/XMLSchema#string